McNeil AB Clinical Pharmacology R&D
Lund, SE-222 20, Sweden
NCT Number: NCT01321931
Multiple-dose nicotine pharmacokinetics with three oral nicotine replacement products. A study in healthy smokers.
Looking for future studies?
Notify Me19 year–50 year
All sexes
Interventional
Phase 1
Lund, SE-222 20, Sweden
Fifty (50) healthy male or female subjects between the ages of 19 and 50 years, inclusive, smoking at least 20 cigarettes daily during at least one year preceding inclusion. Multiple doses of all study treatments are given either every 60 minutes or every 90 minutes, respectively. All products will be administered in accordance with labeling, on five separate treatment visits. The subjects will abstain from smoking from 8 pm in the evening before and until the end of each visit.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
6 mg experimental Nicotine Replacement Therapy (NRT)
Other names: Not yet marketed
Time frame: within the last dosing interval (starting at 10.5-11 hours after first product administration)
Maximum Observed Plasma Concentration (Cmax), which is the maximum (peak) concentration (amount of drug) measurable in blood plasma within the last dosing interval, measured in nanograms/milliliter (ng/mL)
Time frame: within the last dosing interval (starting at 10.5-11 hours after first product administration)
Average Nicotine Plasma Concentration (Cav) within the last dosing interval
Time frame: within the last dosing interval (starting at 10.5-11 hours after first product administration)
Area under the nicotine plasma concentration-vs.-time curve during the last dosing interval (AUCt)
Time frame: During 12 hours post-dose
The time at which maximum concentration is reached (Tmax)
Time frame: within the last dosing interval (starting at 10.5-11 hours after first product administration)
Minimum Observed Plasma Concentration (Cmin), which is the minimum concentration (amount of drug) measurable in blood plasma within the last dosing interval, measured in nanograms/milliliter (ng/mL)
Time frame: within the last dosing interval (starting at 10.5-11 hours after first product administration)
Percent of Peak-Trough Fluctuation in one dosing interval at steady state (PTF)
Time frame: within the last dosing interval (starting at 10.5-11 hours after first product administration)
Swing in one dosing interval at steady state, calculated as (Cmax-Cmin)/ Cmin
Time frame: 30 minutes
The amount of nicotine released from the product during product administration
McNeil AB
Industry
Multiple-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products. A Study in Healthy Smokers.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00968513
Behavior, Chemically-Induced Disorders
Berkeley, California, United States
View Trial DetailsNCT05021185
Behavior, Cancer
San Francisco, California, United States
View Trial DetailsNCT04188197
Behavior, Chemically-Induced Disorders
Charlotte, North Carolina, United States
View Trial DetailsNCT03259360
Behavior, Chemically-Induced Disorders
San Francisco, California, United States
View Trial Details